Showing 1–16 of 22 results
-
3.500,00 د.إThe 24G Pharmacogenomics plus DNA Test is a cutting-edge genetic analysis that provides personalized insights into drug response and overall health. It examines pharmacogenomics, helping to predict how your body metabolizes medications, reducing adverse drug reactions and optimizing treatment plans. Additionally, it includes a comprehensive DNA test covering traits, wellness, and genetic predispositions. Key benefits include personalized medication guidance, enhanced treatment safety, and actionable health insights.
Sample Type : Saliva
Methodology : Illumina
TAT : 3-6 Weeks
-
3.300,00 د.إALK Fusion – FISH is a fluorescence in situ hybridization (FISH) test designed to detect ALK gene rearrangements in tumor samples, primarily for non-small cell lung cancer (NSCLC) patients. Key features include high sensitivity and specificity, FDA approval for clinical diagnostics, and direct visualization of ALK gene fusions at the cellular level.
-
3.250,00 د.إThe BCR/ABL – Quantitative test is a highly sensitive molecular diagnostic assay used to detect and quantify the BCR-ABL fusion gene, a key biomarker in chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). Utilizing real-time PCR technology, it provides precise measurement of BCR-ABL transcript levels, enabling accurate disease monitoring and treatment response assessment.
Sample Type : Whole Blood
Methodology : Real time PCR
TAT : 8-10 Days
-
4.000,00 د.إThe NGS Colorectal Cancer Panel from Lab Tests Dubai is a state-of-the-art genetic test that decodes the unique mutations in your tumor, unlocking critical insights for personalized treatment, targeted therapy selection, and hereditary risk assessment.
-
1.150,00 د.إSample Type : Whole Blood
Methodology : Enzyme-immunoassay
TAT : 10 Days
-
750,00 د.إSample Type : Serum
Methodology : Spectrophotometry
TAT : 10 Days
-
2.820,00 د.إThe HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment.
-
4.000,00 د.إThe **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
-
4.000,00 د.إThe **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
-
950,00 د.إSample Type : Serum
Methodology : Electrophoresis
TAT : 10 Days
-
1.250,00 د.إSample Type : Serum
Methodology : Nephelometry
TAT : 15 Days
-
5.500,00 د.إThe Oncomine Acute Myeloid Leukaemia (AML) Panel is a cutting-edge genetic test that provides a full genomic picture of AML, helping doctors pinpoint key mutations, gene fusions, and copy number changes in genes known to drive the disease. Using advanced next-generation sequencing (NGS), this test delivers fast, precise results, even from limited or degraded sample, so patients get an accurate diagnosis and tailored treatment plans sooner.
-
5.500,00 د.إThe Oncomine Myeloproliferative Neoplasm (MPN) Panel is a cutting-edge genetic test that analyzes key mutations in JAK2, CALR, and MPL, the genes most commonly linked to myeloproliferative disorders. Using advanced next-generation sequencing (NGS), this test provides a highly accurate and efficient way to diagnose and classify MPNs, even when only small or degraded samples are available (as little as 10 ng of DNA or RNA).
-
950,00 د.إSample Type : Serum
Methodology : Immunoturbidometry
TAT : 10 Days
-
3.500,00 د.إThe PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment.
-
1.450,00 د.إSample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
